Neuberger Berman Group LLC, a leading global investment firm, has recently increased its position in Cytosorbents Co. (NASDAQ:CTSO) by 3.3% during Q4 of the financial year 2022. This is in line with the company’s strategy to invest in emerging medical research companies that have shown promise in their respective fields.
Cytosorbents Corp., founded two decades ago by Joseph Rubin, specializes in critical care immunotherapy and the commercialization of blood purification technology. The company’s product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb – revolutionary products at the forefront of saving lives through cutting-edge scientific innovation.
According to SEC filings of June 12th, Neuberger Berman Group LLC now owns a total of 1,529,095 shares of Cytosorbents stock after purchasing an additional 49,525 shares during Q4 2022. This translates to approximately a 3.50% stake worth $2,327,000.
Cytosorbents Co.’s impressive Q1 results have since prompted market speculation as investors anticipate further growth for this promising company. As per reports from NASDAQ on June 14th , NASDAQ:CTSO saw positive trends when it traded up $0.03 on Monday to reach $3.36 – quite a feat considering their yearly low was only $1.03 last year.
This significant investment acquisition demonstrates Neuberger Berman’s faith and trust for Cytosorbents’ potential for profitability and long-term growth sustainability moving forward. Investors predict even greater earnings from this innovative medical research firm in the upcoming years with various ongoing projects that showcase great potential within its industry.
As these technologies continue to evolve and become more refined, it is no surprise that institutional investors like Neuberger Berman are showing an increased interest in emerging technologies that are transforming the medical sector. The future looks bright for Cytosorbents and is another example of how effective technology, innovation, and collaboration have become essential to improving healthcare worldwide.
[bs_slider_forecast ticker=”CTSO”]
Cytosorbents Corp. Gains Attention from Institutional Investors Despite Earnings Struggles
Cytosorbents Corp. has recently gained the attention of institutional investors, as evidenced by recent transactions involving Geode Capital Management LLC, Skylands Capital LLC, Eudaimonia Partners LLC, Avenir Corp, and Renaissance Technologies LLC. These investors have bought and sold shares in the medical research company, with Geode Capital Management LLC increasing its holdings by 0.9%, Skylands Capital LLC growing theirs by 8.3%, Eudaimonia Partners LLC increasing its holdings by 81.8%, Avenir Corp lifting its stake by 6.9%, and Renaissance Technologies LLC raising their holdings by 41.2%. In total, institutional investors currently own 34.04% of Cytosorbents’ stock.
Meanwhile, CFO Kathleen P. Bloch recently acquired 10,000 shares of Cytosorbents stock at an average cost of $3.11 per share for a total transaction of $31,100 in May of this year.
Cytosorbents is engaged in critical care immunotherapy and the commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb.
In terms of earnings data released earlier this year on March 9th for the quarter ending March 2017; Cytosorbents reported ($0.01) earnings per share which beat consensus estimates of ($0.17) earnings per share returning a net margin negative figure but still exceeding return on equity estimated to be standing at 82.56%.
Analysts from firms such as HC Wainwright have recently reiterated a “buy” rating for Cytosorbents’ stock while StockNews.com initiated coverage on the same company with a “hold” rating on May so readers need to perform further research regarding their investment decision as it seems an ambiguous scenario right now about buying, holding or selling the stack of Cytosorbents Corp.